Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Ticlopidine Action Pathway (new)
Homo sapiens
Drug Action Pathway
Ticlopidine is a platelet aggregation inhibitor also known as Ticlid, used to prevent strokes or transient ischemic attacks. It is administered orally as a prodrug that is metabolized into its active form, it then goes on to prevent the binding of ADP to the P2Y receptor. With ADP activation of the receptor inhibited this leads to impaired platelet aggregation and activation. Ticlopidine should be taken with a high fat meal, as it increases absorption of the drug and helps reduce any gastrointestinal irritation.
References
Ticlopidine Pathway (new) References
Storey RF: The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets. 2001 Jun;12(4):197-209. doi: 10.1080/09537100120058739.
Pubmed: 11454254
Boeynaems JM, van Giezen H, Savi P, Herbert JM: P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs. 2005 Mar;6(3):275-82.
Pubmed: 15816504
Gachet C: The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005 Nov;108(2):180-92. doi: 10.1016/j.pharmthera.2005.03.009. Epub 2005 Jun 13.
Pubmed: 15955565
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings